Trials / Completed
CompletedNCT00151034
Trastuzumab (Herceptin), Paclitaxel, Carboplatin and Gemcitabine in Advanced Urothelial Cancer
Phase II Evaluation of Trastuzumab (Herceptin), Paclitaxel, Carboplatin, and Gemcitabine in the Treatment of Advanced Urothelial Cancer
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 33 (actual)
- Sponsor
- University of Michigan Rogel Cancer Center · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Purpose: The purpose of this study is to evaluate the efficacy and safety of treatment with trastuzumab (Herceptin) along with the three other chemotherapy drugs, paclitaxel, carboplatin and gemcitabine, in patients who have advanced urothelial cancer. This clinical trial will also collect information (alternative therapy, response rates, overall survival) from enrolled patients with HER2 negative tumors who are ineligible to receive study treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Trastuzumab | |
| DRUG | Paclitaxel | |
| DRUG | Carboplatin | |
| DRUG | Gemcitabine |
Timeline
- Start date
- 2000-09-01
- Primary completion
- 2004-08-01
- Completion
- 2007-10-01
- First posted
- 2005-09-08
- Last updated
- 2015-01-21
Locations
11 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00151034. Inclusion in this directory is not an endorsement.